Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments by unknown
Wei et al. SpringerPlus  (2016) 5:2083 
DOI 10.1186/s40064-016-3674-3
CASE STUDY
Successful ceritinib treatment in a man 
with MPE and an ALK fusion gene mutation 
after multiple treatments
Hangping Wei, Fangming Du, Yifang Lu, Juan Wei and Xiaofang Dong* 
Abstract 
Introduction:  Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor. It inhibits two of the 
most common ALK-mutants that confer resistance to crizotinib. Ceritinib was approved by Food and Drug Admin-
istration in April 2014. However, the efficacy of ceritinib in Asian patients have not been widely studied. Decrease of 
malignant pleural effusion (MPE) has been rarely reported after treatment with ceritinib.
Case description: A 50-year old man diagnosed with stage IV lung adenocarcinoma presented with MPE and an ALK 
fusion gene mutation. The patient showed partial response to ceritinib after 2-month treatment. Ultrasound showed 
MPE significantly decreased.
Discussion and evaluation: Ceritinib is a good choice, as a targeted therapy, which is more prospect in the 
advanced cancer patients than the traditional therapy.
Conclusion: Ceritinib seems to have a good efficacy in reducing MPE in advanced Asian lung adenocarcinoma 
patients, when other chemotherapy failed.
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Background
During the past decades, platinum-based chemotherapy 
doublets (e.g. cisplatin/pemetrexed and carboplatin/gem-
citabine) was once the standard therapy for non-small-cell 
lung cancer (NSCLC) (Schiller et al. 2002). In recent years, 
treatment paradigm has been changed by identification of 
activating mutations within the epidermal growth factor 
receptor (EGFR) to EGFR tyrosine kinase inhibitors (EGFR-
TKIs). More recently, ALK translocation was described as a 
oncogenic driver in NSCL (Kaczmar and Mehra 2015; Van-
steenkiste 2014). Both echinoderm microtubule-associated 
protein like 4-anaplastic lymphoma kinase and ALK locate 
on chromosome 2. The EML4-ALK fusion gene was found 
in 3–7% of NSCLC patients, who are crizotinib-sensitive. 
Crizotinib is an oral small-molecule TKI that targets ALK, 
which has received accelerated approval from the United 
States FDA (Shaw et al. 2014). However, resistance to crizo-
tinib often occurs after approximately 8-month treatment 
(Muller et  al. 2016). Ceritinib is the second generation of 
ALK inhibitors approved by FDA in April 2014. It inhib-
its two of the most common ALK-mutants that confer 
resistance to crizotinib: L1196M and G1269A, and other 
resistance mutations are C1156Y, S1206Y, 1151Tins and 
G1202R, for example (Shaw et  al. 2016). Ceritinib is 20 
times more potent than crizotinib and has demonstrated 
clinical efficacy in patients with ALK-positive NSCLC who 
have failed therapy with crizotinib (Muller et  al. 2016). 
With these breakthrough discoveries, targeted treatment is 
now widely used in clinical practice, which is more effec-
tive and has less adverse effect than those standard chemo-
therapy (Solomon et al. 2014; Qian et al. 2014). Some study 
showed that ceritinib provided clinically meaningful and 
durable responses with manageable tolerability in chemo-
therapy- and crizotinib-pretreated patients (Nishio et  al. 
2015; Crino et  al. 2016). However, the drug is not still in 
Open Access
*Correspondence:  dydxf123456@163.com 
Department of Medical Oncology, Dongyang People’s Hospital, No. 
60 West Wuning Road, Dongyang 322100, Zhejiang, People’s Republic 
of China
Page 2 of 5Wei et al. SpringerPlus  (2016) 5:2083 
clinical trials in Asian population and the efficacy of reduce 
against MPE has barely be found. We present a case report 
of a 50-year-old man with MPE who is stage IV lung adeno-
carcinoma and an ALK mutation after other multiple treat-
ments showed a good response to ceritinib. Nearly 1 month 
later, the symptoms such as chest distress and tachypnea 
completely disappeared. Two months later, ultrasound 
showed that MPE significantly decreased. The patient dem-
onstrated a partial response (PR).
Case presentation
Nearly 4  years ago, a 47-year-old man presented with a 
2-month history of cough and sputum. A chest comput-
erized tomography (CT) revealed a pulmonary mass in 
the right lung, and pleural and bilateral pulmonary carci-
nomatosis. The biopsy showed that the pulmonary mass 
was adenocarcinoma. Further confirmed by a PET-CT, 
the patient was diagnosed with lung adenocarcinoma with 
multiple metastases (cTxNxM1, Stage IV), involving the 
contralateral lung, bone, adrenal gland and lymph node. 
Molecular testing found the patient was mutation-type of 
ALK translocation. The patient is asymptomatic and with a 
stable general condition. The patient was treated with six-
course chemotherapy of cisplatin/pemetrexed. PR showed 
after the first two-course treatment with RECIST1.1 cri-
teria. One year later, the patient showed pulmonary pro-
gression and started to receive crizotinib, which achieved 
stable disease (SD) as the maximum response, accoeding 
to the RECIST1.1 criteria. After 1  year, magnetic reso-
nance imaging (MRI) revealed brain metastases. So the 
patient initiated whole brain radiotherapy combination 
with temozolomide (150  mg  m−2, 28  days for a cycle), 
followed by the other chemotherapy with two-course of 
carboplatin and gemcitabine to consolidate the curative 
effect and to stability the lung lesions, using SD as the 
maximum response with RECIST1.1 criteria. Six months 
later, the patient showed pulmonary progression and ini-
tiated the other chemotherapy with four-course of cispl-
atin/pemetrexed, with SD as the response, according to 
the RECIST1.1 criteria. Eight months later, the patient, a 
51-year-old man, showed clinical progression with the 
symptoms such as serious chest distress and tachyp-
nea. Ultrasound revealed bilateral bulk pleural effusion. 
The right diameter of anteroposterior and vertical were 
respectively 127 and 130 mm, and in the left were 89 and 
94 mm. Due to the poor general condition (ECOG PS is 
three point), ceritinib, buyed from Hong Kong, 750  mg 
once daily was started. One month later, symptoms like 
chest distress and tachypnea completely disappeared. 
Ultrasound showed that pleural effusion significantly 
reduced (Fig.  1). The diameter of anteroposterior and 
vertical respectively were 98 and 76 mm in the right, and 
33 and 71  mm in the left. Two months later, ultrasound 
revealed small amount of pleural effusion, indicating that 
bulk pleural effusion was nearly completely disappeared 
(Fig.  2), with II degree of nausea. During the treatment 
process, selected tumor markers were also significantly 
reduced, which were summarized in Table  1. Change 
curve of tumor marker (CEA and CA125) was presented 
in Figs. 3 and 4. Currently, the patient demonstrated a PR, 
according to Response Evaluation Criteria in Solid Tumors 
(RECIST 1.1), and have a very good general status (Kar-
nofsky 80–90%).     
Discussion
 Discovery of oncogenic drivers has revolutionized man-
agement strategy for various cancer patients (Sereno 
et  al. 2015). Moreover, development of personalized 
Fig. 1 Ultrasound on September 7 2015 showed that the diameter 
of anteroposterior and vertical respectively was 98 and 76 mm in the 
right, and 33 and 71 mm in the left (1 month later)
Fig. 2 Ultrasound on October 17 indicated that bilateral bulk pleural 
effusion was almost completely disappeared (2 months later)
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Table 1 The tumor markers were significantly reduced during the treatment progress
Time 8/1 8/28 9/7 10/17 11/20 12/21
CEA (ng/ml) 61.11 24.66 13.85 7.15 3.3 2.81
CA125 (U/ml) 813.8 242.9 188.1 167 102.9 89.6
Fig. 3 Curve of CEA level during the treatment
Fig. 4 Curve of CA125 level during the treatment
Page 4 of 5Wei et al. SpringerPlus  (2016) 5:2083 
medicine of lung adenocarcinoma, the discovery of vari-
ous genetic alterations that promote cancer growth and 
survival, such as EGFR mutations and EML4-ALK rear-
rangements, have revolutionized treatment paradigms 
for patients (Kwak et al. 2010). Targeted therapies signif-
icantly increase disease-free survival (DFS) and overall 
survival (OS) compared to conventional chemotherapy 
such as platinum-based chemotherapy. Chromosomal 
rearrangements of a ALK were detected in 1.6–8.6% of 
unselected NSCLC patients (Scagliotti et al. 2012; Forde 
and Rudin 2012). Crizotinib, a druggable ALK recep-
tor tyrosine kinase for cancer treatment, have been 
approved for the treatment of metastatic NSCLC, with 
marked improvement of progression-free survival of 
patients (Chan et  al. 2016). A subsequent clinical trial 
established crizotinib as the first-line treatment for ALK 
positive NSCLC. The PFS of crizotinib is 10.9  months 
while patients using standard platinum doublet therapy 
with either cisplatin or carboplatin and pemetrexed only 
achieved 7.0  months (Solomon et  al. 2014). Unfortu-
nately, crizotinib resistance inevitably occurred. In gen-
eral, mechanisms of acquired drug resistance could be 
classified into two main categories. The target gene itself 
could be altered either by mutation or by amplification. 
On the other hand, tumor cells might lose their depend-
ency from the inhibited signaling pathway by activating 
alternative signaling pathways (Rothschild and Gautschi 
2013). In up to one-third of relapsing patients, crizotinib 
resistance is mediated by secondary resistance muta-
tions located in the ALK tyrosine kinase domain. The 
most commonly identified resistance mutation is the 
gatekeeper mutation L1196M and G1269A (Solomon 
et al. 2014). Thanks to better understanding of resistance 
mechanisms to crizotinib, new therapeutic approaches 
have been developed. The development of acquired 
resistance, however, poses a serious clinical challenge.
Ceritinib (LDK378, Zykadia®, Novartis Pharmaceu-
ticals, Basel, Switzerland) is an oral, small-molecule, 
ATP-competitive, TKI of ALK. In preclinical trials, ceri-
tinib seems to be a more potent ALK inhibitor than cri-
zotinib (Doebele et  al. 2012). Furthermore, ceritinib is 
able to overcome resistance to crizotinib. The US FDA 
granted accelerated approval to ceritinib in April 2014 
based on several promising clinical trials mentioned 
below. Shaw et  al. reported landmark ASCEND-1 study 
in March 2014. Among 114 patients, 1 achieved com-
plete response, 65 partial responses (57%) and 25 (22%) 
instances of stable disease. In addition, two clinical tri-
als have provide ceritinib have meaningful and durable 
responses in Asian patients (Nishio et  al. 2015; Crino 
et  al. 2016). In this case, patient achieved the second 
PR, after the first chemotherapy, while others with SD. 
MPE and tumor markers were significantly reduced. It is 
worth mentioned that score of Questionnaire of Quality 
of Life (QQL) in this case was significant improved. It is 
more important in the advanced cancer patients than the 
evaluation index such as PFS or OS. There was a point 
to dose about ceritinib in Asian people. The body surface 
area of the patient is 1.9, similar to that of the Americans’ 
but larger than the average of Asian people. The above 
two clinical trials, Ceritinib maximum-tolerated dose 
was 750  mg once daily in Asian patients (Nishio et  al. 
2015; Crino et  al. 2016). Of course, it should be noted 
that studies with larger samples and the doses should be 
performed to get more accurate results.
In this case, it should also be noticed that targeted ther-
apy is a good choice, after multiple treatments. So, targeted 
therapy is the trend of the development of lung cancer. 
However, two clinically validated and FDA approved lung 
cancer predictive biomarkers (EGFR and ALK transloca-
tions) occur in only about 20% of lung adenocarcinomas 
and acquired resistance develops to first generation drugs 
(Cagle et  al. 2016). More biomarkers and targeted drugs 
should be found. Maybe newer ALK-TKIs like ASP3026, 
AP26113, and X-396 will be of benefit for these patients.
Conclusion
This patient showed a quick and significant response to 
ceritinib during 2  months and a marked reduction of 
MPE and tumor marker a few days after starting ceri-
tinib. It suggests that ceritinib have a good efficacy 
against MPE in advanced lung adenocarcinoma in Asian 
Patients, even if failed with other multimodal treatments.
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